The LCCG meta-analysis did show a significant trend (p = 0.002) against the adoption of adjuvant chemotherapy in patients with a worsening performance status (PS) [ 23 ] In this regard, LACE subgroup analysis showed increasing benefits from adjuvant chemotherapy with better PS (0 vs 1), with a detrimental effect for PS 2 (test for trend p = .009 for OS) [ 18 ].
A highly significant interaction according to stage and nodal status was detected, indicating a substantial absence of PORT effect in stage III or N2 patients (HR 0.99 and 0.97), restricting the detrimental difference to lower stage disease [ 39 ].
Although unpowered to assess the prognostic or predictive impact of EGFR mutation and copy number, a possible trend toward a positive predictive role of the mutation (and copy number) was proposed in JBR10. • LACE BIO (ANITA, JBR10, IALT and CALBG 9633) : High class III beta tubulin (TUBB3) expression maintained the negative prognostic impact seen in previous analysis (HR for death = 1.3; p = .001).